The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
No Access

A naturalistic outcome study of risperidone treatment among hospital patients

Published Online:https://doi.org/10.1176/ps.47.10.1118

Risperidone, an atypical antipsychotic, was introduced into clinical use in New York State facilities in April 1994. In this chart review study, records were reviewed for the first 63 patients started on risperidone at the Bronx Psychiatric Center during 1994. Sixty percent of patients treated with risperidone had a positive outcome, indicated by clinical improvement either at discharge or in the hospital. Twenty- two percent required termination of risperidone treatment within the initial three months. Risperidone appeared to be associated with favorable outcome among chronic state hospital patients, including those not discharged within the first three months of treatment.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.